0M61 Stock Chart & Stats
€1.37
-€0.05(-5.95%)
At close: 4:00 PM EDT
€1.37
-€0.05(-5.95%)
Day’s Range― - ―
52-Week Range€0.54 - €1.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€57.54M
Enterprise Value€51.03M
Total Cash (Recent Filing)€13.45M
Total Debt (Recent Filing)€20.08M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 11, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding39,607,853
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.34
Price to Sales (P/S)0.93
P/FCF Ratio-2.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.12Price Target Upside200.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.27
Revenue Forecast (FY)€38.87M
Bulls Say, Bears Say
Bulls Say
Specialized MyoPro ProductThe MyoPro addresses a defined need among people with neuromuscular disorders and upper-limb weakness, using powered assistance and EMG detection to support daily activities. This specialized medical-device positioning can help distinguish the company from less targeted assistive-technology offerings over the medium term.
Revenue Scale And GrowthRevenue has scaled meaningfully to $43.3 million and continues to grow, indicating an established commercial base for MyoPro rather than an entirely early-stage product. Continued expansion can provide operating leverage opportunities if the company controls costs and converts more revenue into profit.
Strong Gross MarginA gross margin near 68% means a substantial share of product revenue remains after direct costs, supporting investment in commercialization, fitting, and patient support. The margin profile provides a foundation for future operating improvement, although durable profitability still depends on reducing overhead and losses.
Bears Say
Persistent Operating LossesLarge operating and net losses show that the company has not yet demonstrated durable operating leverage despite revenue growth and strong gross margins. Continued losses can restrict internal funding capacity, increase dependence on external capital, and make future earnings improvement dependent on substantial cost discipline.
Worsening Cash BurnNegative operating and free cash flow indicate that current operations are consuming cash rather than self-funding growth. The roughly 49% deterioration in free cash flow heightens the need for financing or improved execution, potentially limiting investment flexibility while losses persist over the next several quarters.
Higher Leverage And Shrinking EquityRising debt alongside a shrinking equity base reduces balance-sheet flexibility and increases financing risk if operating losses continue. Higher leverage can place more pressure on future cash flows and constrain capital allocation, making the company more vulnerable to funding needs during its path toward profitability.
Myomo News
0M61 FAQ
What was Myomo Inc’s price range in the past 12 months?
Myomo Inc lowest stock price was €0.54 and its highest was €1.60 in the past 12 months.
What is Myomo Inc’s market cap?
Myomo Inc’s market cap is €57.54M.
When is Myomo Inc’s upcoming earnings report date?
Myomo Inc’s upcoming earnings report date is Nov 11, 2026 which is in 36 days.
How were Myomo Inc’s earnings last quarter?
Myomo Inc released its earnings results on Aug 05, 2026. The company reported -€0.08 earnings per share for the quarter, beating the consensus estimate of -€0.087 by €0.007.
Is Myomo Inc overvalued?
According to Wall Street analysts Myomo Inc’s price is currently Undervalued.
Does Myomo Inc pay dividends?
Myomo Inc does not currently pay dividends.
What is Myomo Inc’s EPS estimate?
Myomo Inc’s EPS estimate is -0.07.
How many shares outstanding does Myomo Inc have?
Myomo Inc has 39,607,853 shares outstanding.
What happened to Myomo Inc’s price movement after its last earnings report?
Myomo Inc reported an EPS of -€0.08 in its last earnings report, beating expectations of -€0.087. Following the earnings report the stock price went up 32.745%.
Which hedge fund is a major shareholder of Myomo Inc?
Currently, no hedge funds are holding shares in DE:0M61
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Myomo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€4.12 (200.80% Upside)
€4.12 (200.80% Upside)
Blogger Sentiment
Bullish
DE:0M61 Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth €45.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Myomo Inc
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
0M61 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights steady, incremental progress: modest top-line growth (Q1 revenue +3%), improved gross margin (+100 bps), lower operating expenses (-1%), improved adjusted EBITDA (negative $2.3M vs negative $2.8M), strong shifts toward recurring revenue (49% of revenue vs 25% prior year), and robust international and O&P channel growth (international +53% YoY; U.S. O&P +79% YoY). Management provided constructive operational updates including payer contracting (covered lives up to 158M), product advances (mobile app reducing material costs ~10%, MyoPro 3 development), and a growing referral network (150+ rehab facilities, Autoboc partnership). Lowlights include continued net losses, dependency on a multi-quarter revenue cycle, macro pressures in Medicare Advantage and a decline in Medicare Part B dollar contribution, and some short-term margin pressure from higher on-site fitting costs. Overall, positive operational momentum and improving financial metrics outweigh remaining profitability and execution risks.View all DE:0M61 earnings summaries0M61 Stock 12 Month Forecast
Average Price Target
€4.12
▲(200.80% Upside)